tamarisktechnologiesgroup.com rapport :   Visitez le site

Données techniques du tamarisktechnologiesgroup.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte tamarisktechnologiesgroup.com.Actuellement, hébergé dans United States et son fournisseur de services est GoDaddy.com LLC .

the related websites

domaine	Titre
tamarisktechnologiesgroup.com	mxba™ oral drug delivery system | tamarisk tech group
drug-dev.com	drug development & delivery - the latest methods in drug development
nemera.net	nemera : we put patients first - drug delivery devices
testclear.com	pass a drug test with our proven drug testing and detoxification solutions
thediversioncenter.com	diversion center: drug and alcohol evaluation | drug addiction classes
oralsurgeonfinder.org	oral surgeon finder - find the best oral surgeons near you
dearlunch.com	lunch delivery in nairobi | affordable meals, fast free delivery
deliveryemsorocaba.com.br	delivery em sorocaba - delivery de comida - encontre o que pedir, aonde ir e aon
letsrunmario.com	instant delivery services in pune same day delivery within 2 hours
purifiedwaterdelivery.com	purified water delivery service & office water delivery - water delivery service
giaphaweb.net	local flower delivery seattle | same day flower delivery
acmewaterworld.com	acme water bottled water delivery & water filtration - water delivery service &
oralcarezone.com	oral care zone
alcoholdrugevaluations.com	alcohol and drug evaluations - alcohol and drug evaluations $105
asapdrugtest.com	a.s.a.p drug testing services

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

call us : 702.516.6451 mail us : info@tamarisktechgroup.com menu skip to content home technology about partners contact search for: developing technology for the future and delivering viable solutions today tamarisk's patented, broad-spectrum oral drug delivery system is highly resistant to gastric disentegration and significantly increases bioavailability of a given therapeutic. it can be used with both small and large molecules, including incretin-like peptides such as glp and gip discover more next generation oral drug delivery the mxba™ platform is a drug delivery technology that uses a strategic combination of natural excipients to empower novel gi transcytosis mechanisms, resulting in increased oral bioavailability. contact maximum bioavailability mxba™ the objective is not to merely enhance oral drug delivery but to tackle delivery of some of the world's most difficult apis using our patented oral drug delivery system. read more the solution for proteins, peptides, and monoclonal antibodies "the tamarisk oral drug delivery platform is a game changer." discover more announcement | delegates from tamarisk will be attending bio 2018! delegates will also be participating in the 1-on-1 partnering sessions and are quite enthusiastic to share more about our recent critical advances with the mxba technology. if you would like to schedule a meeting to learn more, please contact us today. mxba™ platform | maximum bioavailability (revised 04.29.16) oral drug delivery technology | click here press release | los angeles, april 25, 2016 oral drug delivery system | “independent rat study finds 54% oral insulin relative bioavailability using tamarisk’s mxba™ platform technology” click here or play video shareholder relations get the latest updates | click here new oral drug delivery system | tamarisk’s mxba™ platform tamarisk technologies group is an early stage drug delivery technology company with headquarters based in santa barbara, california. our patented mxba™ oral drug delivery system is a platform technology that maximizes the bioavailability of a wide range of oral drugs, including both small molecules and larger bio-molecules and bcs classes ii & iv drugs. at the core of tamarisk’s mxba™ technology is an alginate particle carrier designed to encapsulate, protect and transport payload drug candidates within the gi. unique to tamarisk are the added excipient substrates engineered into the particles to provide targeted gi delivery, added preservation and transfer of payload drugs and facilitation of novel absorption pathways. by increasing absorption and bioavailability on currently difficult to administer therapeutics, tamarisk’s mxba™ oral drug delivery system will be the next generation enabler for the pharmaceutical industry. to date, tamarisk has conducted numerous bench, cell culture, and small animal studies that confirm our particle consistently delivers significantly better than the control. in a rat study recently performed at charles river, the system was used to study the increased bioavailability of resveratrol, confirming previously observed results. however, tamarisk is now primarily focused on completing it’s work with oral protein delivery, and based on numerous studies conducted, we are confident the mxba™ oral drug delivery platform will soon be a preferred solution for use with both small and large molecules, including incretin-like peptides such as glp and gip. solving the problem because of the various challenges an orally administered drug faces on its journey through the gi, normally only a small percentage of the payload will reach the bloodstream in a desired bioactive form. this is substantially reduced when the drug’s structure is both unfamiliar and quantitatively challenging to the normal gi absorption mechanisms. these challenges require many next generation drugs, such as peptides, proteins and monoclonal antibodies, to be administered through undesirable injection technologies or in such large oral dosages that patients are exposed to a myriad of undesirable side effects. effective oral bioavailability will drive a major surge in acceptance, patient compliance and sales for these high valued drugs. tamarisk technologies is well positioned to capitalize on its disruptive broad-spectrum mxba™ platform technology to build a portfolio of drug delivery partnership opportunities with a multitude of pharmaceutical companies. products/services tamarisk has developed and patented a platform oral drug delivery system that uses a strategic combination of natural excipients to empower novel gi transcytosis mechanisms, resulting in substantially increased oral bioavailability. target markets: small molecule pharmaceuticals over-the-counter vitamins and nutraceuticals biologics (proteins/peptides, monoclonal antibodies) generics vaccines all rights reserved. unless otherwise noted, copyrights for the documents, logos, and graphic designs available on this web site are owned by tamarisk technologies group, llc. current events june 4-7, 2018 bio 2018 boston, ma tamarisk’s oral drug delivery system  tamarisk's novel, patent pending mxba™ (maximum bioavailability) delivery platform focuses on increasing the bioavailability of oral drugs. our delivery mechanism has proven effective on the span of drug formulations from small molecules to larger bio-molecules, including bcs classes ii & iv drugs. site map about contact home oral drug delivery system | mxba™ partners partners privacy tamarisk’s oral insulin delivery updates from the lab october 2018 m t w t f s s 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 copyright © tamarisk technologies group | oral drug delivery powered by wordpress , designed and developed by templatesnext menu home technology about partners contact

Analyse PopURL pour tamarisktechnologiesgroup.com

http://www.tamarisktechnologiesgroup.com/privacy/
http://www.tamarisktechnologiesgroup.com/partners-2/
http://www.tamarisktechnologiesgroup.com/updates-mxba-oral-delivery/
http://www.tamarisktechnologiesgroup.com/wp-content/uploads/2015/11/mxba-logo.jpg
http://www.tamarisktechnologiesgroup.com/contact/
http://www.tamarisktechnologiesgroup.com/#content
http://www.tamarisktechnologiesgroup.com/oral-drug-delivery-technology/
http://www.tamarisktechnologiesgroup.com/oral-insulin-delivery/
http://www.tamarisktechnologiesgroup.com/wp-content/uploads/2015/11/2page-img1.jpg
http://www.tamarisktechnologiesgroup.com/partners/
http://www.tamarisktechnologiesgroup.com/oral-drug-delivery-system/
http://www.tamarisktechnologiesgroup.com/wp-content/uploads/2015/11/tamariskbw.jpg
http://www.tamarisktechnologiesgroup.com/about/

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: TAMARISKTECHNOLOGIESGROUP.COM
Registrar URL: http://www.godaddy.com
Registrant Name: AT SNOOTS II
Registrant Organization:
Name Server: NS71.DOMAINCONTROL.COM
Name Server: NS72.DOMAINCONTROL.COM
DNSSEC: unsigned

For complete domain details go to:
http://who.godaddy.com/whoischeck.aspx?domain=TAMARISKTECHNOLOGIESGROUP.COM

The data contained in GoDaddy.com, LLC's WhoIs database,
while believed by the company to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This
information is provided for the sole purpose of assisting you
in obtaining information about domain name registration records.
Any use of this data for any other purpose is expressly forbidden without the prior written
permission of GoDaddy.com, LLC. By submitting an inquiry,
you agree to these terms of usage and limitations of warranty. In particular,
you agree not to use this data to allow, enable, or otherwise make possible,
dissemination or collection of this data, in part or in its entirety, for any
purpose, such as the transmission of unsolicited advertising and
and solicitations of any kind, including spam. You further agree
not to use this data to enable high volume, automated or robotic electronic
processes designed to collect or compile this data for any purpose,
including mining this data for your own personal or commercial purposes.

Please note: the registrant of the domain name is specified
in the "registrant" section. In most cases, GoDaddy.com, LLC
is not the registrant of domain names listed in this database.

  REGISTRAR GODADDY.COM, LLC

  REFERRER http://www.godaddy.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =tamarisktechnologiesgroup.com

  PORT 43

  SERVER whois.godaddy.com

  ARGS tamarisktechnologiesgroup.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME tamarisktechnologiesgroup.com

NSERVER

  NS71.DOMAINCONTROL.COM 216.69.185.46

  NS72.DOMAINCONTROL.COM 208.109.255.46

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientRenewProhibited https://icann.org/epp#clientRenewProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2015-05-05

  CREATED 2014-02-17

  EXPIRES 2018-02-17

OWNER

ADMIN

TECH

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.